Product Description
Rasburicase, a recombinant urate oxidase, has been shown to be effective in lowering uric acid and preventing uric acid accumulation in patients with hematologic malignancies who had hyperuricemia or who were at high risk for developing hyperuricemia. It has been approved for pediatric use in the US. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/12841818/)
Mechanisms of Action: Uric Acid Oxidizer
Novel Mechanism: No
Modality: Coagulation Factor
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Approved
Approved Countries: Argentina | Australia | Austria | Belgium | Brazil | Canada | Croatia | Cyprus | Czech | Denmark | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Ireland | Italy | Korea | Latvia | Lithuania | Luxembourg | Netherlands | New Zealand | Norway | Poland | Portugal | Saudi Arabia | Singapore | Slovakia | Slovenia | Sweden | Switzerland | Taiwan | Turkey | United Kingdom | United States
Approved Indications: Leukemia | Lymphoma | Oncology Solid Tumor Unspecified | Oncology Unspecified
Known Adverse Events: Abdominal Pain | Headache | Pain Unspecified | Hypophosphatemia | Laryngeal Cancer | Oncology Unspecified | Laryngeal Edema | Constipation | Diarrhea | Edema
Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|